Tendency of Semaglutide to Induce Gastroparesis: A Case Report
Ahtshamullah Chaudhry, Buluku Gabriel, Jawad Noor, Saima Jawad, Suryanarayana Reddy Challa
Abstract
Semaglutide, an agonist of the glucagon-like peptide-1 receptor, is frequently used in the treatment of diabetes mellitus type 2, although, lately, weight loss has additionally become a reason for its use. However, if a patient is already experiencing bloating, nausea, abdominal pain, and discomfort in the abdomen, it is not recommended to use it due to concern about aggravating these symptoms. Although it is often well tolerated, there are occasions when it can have several gastrointestinal side effects. Therefore, we report a case of a patient who started taking semaglutide and later developed gastroparoresis.
Topics & Concepts
SemaglutideBloatingMedicineGastroparesisNauseaAbdominal painType 2 diabetesWeight lossLiraglutideDiabetes mellitusGlucagon-like peptide 1 receptorAbdomenAgonistInternal medicineGastric emptyingSurgeryEndocrinologyReceptorObesityStomachDiabetes Treatment and ManagementHelicobacter pylori-related gastroenterology studiesGastrointestinal motility and disorders